Articles with public access mandates - Roger S. Lo, MD., PhDLearn more
Available somewhere: 71
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
Mandates: US National Institutes of Health
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
Mandates: US National Institutes of Health
Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation
R Nazarian, H Shi, QI Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ...
Nature 468 (7326), 973-977, 2010
Mandates: US National Institutes of Health
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression
A Garcia-Diaz, DS Shin, BH Moreno, J Saco, H Escuin-Ordinas, ...
Cell reports 19 (6), 1189-1201, 2017
Mandates: US National Institutes of Health
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
Mandates: US National Institutes of Health
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
M Krauthammer, Y Kong, BH Ha, P Evans, A Bacchiocchi, JP McCusker, ...
Nature genetics 44 (9), 1006-1014, 2012
Mandates: US National Institutes of Health, National Health and Medical Research …
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ...
New England Journal of Medicine 366 (3), 207-215, 2012
Mandates: US National Institutes of Health, Cancer Research UK
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
DS Shin, JM Zaretsky, H Escuin-Ordinas, A Garcia-Diaz, S Hu-Lieskovan, ...
Cancer discovery 7 (2), 188-201, 2017
Mandates: US National Institutes of Health, V Foundation, USA
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ...
Cancer discovery 4 (1), 80-93, 2014
Mandates: US National Institutes of Health, National Health and Medical Research …
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
H Shi, G Moriceau, X Kong, MK Lee, H Lee, RC Koya, C Ng, T Chodon, ...
Nature communications 3 (1), 724, 2012
Mandates: US National Institutes of Health
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
J Müller, O Krijgsman, J Tsoi, L Robert, W Hugo, C Song, X Kong, ...
Nature communications 5 (1), 5712, 2014
Mandates: US National Institutes of Health, European Commission, Dutch Cancer Society
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
W Hugo, H Shi, LU Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ...
Cell 162 (6), 1271-1285, 2015
Mandates: US National Institutes of Health
Therapy-induced tumour secretomes promote resistance and tumour progression
AC Obenauf, Y Zou, AL Ji, S Vanharanta, W Shu, H Shi, X Kong, ...
Nature 520 (7547), 368-372, 2015
Mandates: US National Institutes of Health, Howard Hughes Medical Institute, Austrian …
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction
G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ...
Cancer cell 27 (2), 240-256, 2015
Mandates: US National Institutes of Health
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
A Kaur, MR Webster, K Marchbank, R Behera, A Ndoye, CH Kugel, ...
Nature 532 (7598), 250-254, 2016
Mandates: US National Institutes of Health
MDM4 is a key therapeutic target in cutaneous melanoma
A Gembarska, F Luciani, C Fedele, EA Russell, M Dewaele, S Villar, ...
Nature medicine 18 (8), 1239-1247, 2012
Mandates: US National Institutes of Health, National Health and Medical Research …
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
DB Johnson, AM Menzies, L Zimmer, Z Eroglu, F Ye, S Zhao, H Rizos, ...
European journal of cancer 51 (18), 2792-2799, 2015
Mandates: US National Institutes of Health
Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation
M Pan, MA Reid, XH Lowman, RP Kulkarni, TQ Tran, X Liu, Y Yang, ...
Nature cell biology 18 (10), 1090-1101, 2016
Mandates: US National Institutes of Health
Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
TJ Parmenter, M Kleinschmidt, KM Kinross, ST Bond, J Li, MR Kaadige, ...
Cancer discovery 4 (4), 423-433, 2014
Mandates: US National Institutes of Health, National Health and Medical Research …
Publication and funding information is determined automatically by a computer program